Cyxone's T20K development drug in 87 different pharmacological tests
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.
T20K has undergone extensive testing, amounting to a total of 87 different test systems. Cyxone has selected those pharmacological tests that are likely to have the greatest potential of being affected by the company's development substance.
The tests suggest that T20K does not bind, or binds weakly, to the studied cellular receptors. Furthermore, the majority of such receptors are found in tissue to which a relatively large molecule such as T20K is not expected to be able to be distributed.
In Cyxone's judgement, T20K is unlikely to cause side effects through any effect on the studied receptors of primarily human cells.
October 23, 2017
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0)723 816168
211 22 Malmö
This is information that Cyxone AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on October 23, 2017 at 14:15 CET.
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of substances that inhibit key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank, which can be reached on +46 (0) 8 46 38 000.